Clinical trials: Sorafenib
Healthy
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
The study aims to assess the pharmacokinetics and safety of DPH001, an amorphous formulation of sorafenib, compared to Nexavar® in healthy volunteers.
- Trial name
- NCT06797427
- Testing
- DPH001, Nexavar (Sorafenib)
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Disruptive Pharma
Pharmacokinetics, Bioavailability
Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects
This is a single centre, open-label, randomised, single dose, 3-way crossover comparative (PK) and bioavailability study in healthy male subjects comparing a 200 mg Sorafenib (Nexavar®) reference tablet (Regimen A) to XS005…
- Trial name
- NCT05967377
- Testing
- Sorafenib - Period 1, XS005 Sorafenib Capsule A - Period 1, XS005 Sorafenib Tablet A - Period 1
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Xspray Pharma AB
Hepatocellular Carcinoma
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment.
- Trial name
- NCT04229355
- Testing
- DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
T Cell Lymphoma
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
This study will be a pilot study of sorafenib 400mg PO twice daily in refractory T-cell lymphomas including peripheral T-cell lymphoma (PTCL), angioimmunoblastic lymphadenopathy (AILD), cutaneous T cell lymphoma (CTCL)…
- Trial name
- NCT01561833
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Yale University
Hepatocellular Carcinoma
Adjuvant Therapies for Patients With HCC and MVI
Hepatocellular carcinoma (HCC) is a common malignancy, and its incidence is expected to increase in many countries in coming decades.
- Trial name
- A-TACE/S-HCC (NCT02436902)
- Testing
- TACE, Sorafenib, TACE plus sorafenib
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Healthy, Male
Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers
The purpose of this study is to evaluate the pharmacokinetics characteristics ,tolerability, and safety after orally administrating SYO-1644 to healthy male volunteers in randomized, active-controlled, open-label clinical study.
- Trial name
- NCT03674060
- Testing
- SYO-1644, Nexavar tab
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Samyang Biopharmaceuticals Corporation
Biological Availability
Relative Bioavailability of Sorafenib Tablet for Oral Suspension
The primary objective of the study is to Investigate the relative bioavailability of sorafenib as 400 mg (4 x 100 mg) tablet for oral suspension formulation in comparison to 400 mg (2 x 200 mg) marketed tablet formulation.
- Trial name
- NCT02538393
- Testing
- Sorafenib (BAY43-9006) Film-coated tablet, Sorafenib (BAY43-9006) Oral suspension
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bayer
Fasting
Bioequivalence Study of Sorafenib Tablet and Nexavar
Randomized, open-label, 3-way reference replicated crossover bioequivalence study of sorafenib 200 mg tablet and nexavar (reference) following a 200 mg dose in healthy subjects under fasting conditions.
- Trial name
- NCT02599337
- Testing
- Nexavar, Sorafenib
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Yabao Pharmaceutical Group
Drug Interactions
Sorafenib Drug Drug Interaction Study in Healthy Male Subjects
To evaluate the effect of levothyroxine on the absorption, distribution, metabolization and elimination of sorafenib and safety in healthy male subjects
- Trial name
- NCT02332031
- Testing
- Sorafenib (Nexavar, BAY43-9006), Levothyroxine
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bayer
Hepatocellular Cancer, Non-small Cell Lung Cancer
Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
Tumour angiogenesis has been identified to play a critical role in tumour growth and this knowledge has led to the identification of new targets for cancer therapy.
- Conditions
- Hepatocellular Cancer, Non-small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer
- Trial name
- NCT01507740
- Testing
- Avastin, Suntent, Nexavar
- Where
- Austria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Liver Disease
Hepatic Impairment Study
This study is to find out how the subject's body processes and reacts to the study drug, and to find out how long it remains in the subjects system after one dose.
- Trial name
- NCT00829231
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 3 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Myeloma
Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients
This is a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. The initial patients on the dose-finding portion of this study will be enrolled through a single institution.
- Trial name
- NCT00536575
- Testing
- Bortezomib, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- SCRI Development Innovations, LLC
Malignant Melanoma
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
The purpose of this study is to compare the effects, good and/or bad, of Carboplatin and ABI-007 (Abraxane) in combination with Sorafenib (BAY 43-9006) on Melanoma.
- Trial name
- NCT00483301
- Testing
- Sorafenib (BAY 43-9006), ABI-007(Abraxane)
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Mt. Sinai Medical Center, Miami